City Therapeutics, Inc. filed a Current Report on Form 8-K on November 10, 2026, disclosing that it issued a press release announcing the first participant dosed in a Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease.
Key Highlights
- First participant dosed: City Therapeutics announced that the first participant has been dosed in its Phase 1 clinical trial of CITY-RBP4.
- Target indication: The trial targets Stargardt disease, according to the filing.
- Disclosure mechanism: The announcement was made via a press release issued on November 10, 2026, furnished as Exhibit 99.1.
- Emerging growth company: The registrant identified itself as an emerging growth company under applicable SEC rules.
- Signing officer: The report was signed by Mary Beth DeLena, Chief Legal Officer and Secretary, on November 10, 2026.
City Therapeutics Reports Phase 1 Milestone for CITY-RBP4 in Stargardt Disease
City Therapeutics, Inc. (NASDAQ:CTY), headquartered at 399 Binney Street, Cambridge, Massachusetts 02142, filed a Current Report disclosing a clinical development milestone. According to the filing, the company issued a press release on November 10, 2026, entitled "City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease."
The filing was made under Item 7.01 (Regulation FD Disclosure), and the press release was furnished as Exhibit 99.1. The company disclosed that the information furnished under Item 7.01 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not subject to the liabilities of that section unless expressly incorporated by reference in a subsequent filing.
City Therapeutics indicated that it is an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. The company also indicated that it has not elected to use the extended transition period for complying with new or revised financial accounting standards. The report was authorized and signed by Chief Legal Officer and Secretary Mary Beth DeLena on behalf of the registrant.
What Was Disclosed
City Therapeutics filed an 8-K on November 10, 2026, to disclose under Regulation FD that the first participant had been dosed in a Phase 1 clinical trial of CITY-RBP4 for Stargardt disease, with the supporting press release furnished as Exhibit 99.1.




Please wait processing your request...